Shares of GW Pharmaceuticals PLC- (NASDAQ:GWPH) have received an average rating of “Buy” from the fourteen research firms that are covering the firm, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $178.70.
GWPH has been the topic of several analyst reports. Cantor Fitzgerald lowered their price target on shares of GW Pharmaceuticals PLC- from $211.00 to $193.00 in a report on Sunday, December 9th. ValuEngine lowered shares of GW Pharmaceuticals PLC- from a “strong-buy” rating to a “buy” rating in a report on Wednesday, January 2nd. BidaskClub raised shares of GW Pharmaceuticals PLC- from a “hold” rating to a “buy” rating in a report on Thursday, January 17th. Zacks Investment Research raised shares of GW Pharmaceuticals PLC- from a “hold” rating to a “buy” rating and set a $165.00 price target on the stock in a report on Wednesday, February 6th. Finally, Guggenheim initiated coverage on shares of GW Pharmaceuticals PLC- in a report on Friday, February 22nd. They issued a “buy” rating and a $178.00 price target on the stock.
Get GW Pharmaceuticals PLC- alerts:In other news, insider Volker Knappertz sold 4,140 shares of the company’s stock in a transaction dated Tuesday, February 26th. The shares were sold at an average price of $12.46, for a total value of $51,584.40. Following the sale, the insider now owns 9,612 shares of the company’s stock, valued at approximately $119,765.52. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Justin D. Gover sold 22,620 shares of the company’s stock in a transaction dated Wednesday, February 13th. The stock was sold at an average price of $12.50, for a total transaction of $282,750.00. Following the completion of the sale, the chief executive officer now directly owns 370,445 shares in the company, valued at approximately $4,630,562.50. The disclosure for this sale can be found here. Insiders sold a total of 65,724 shares of company stock worth $726,242 in the last three months. Insiders own 5.50% of the company’s stock.
Institutional investors and hedge funds have recently bought and sold shares of the company. Mckinley Capital Management LLC Delaware bought a new stake in shares of GW Pharmaceuticals PLC- in the 4th quarter worth about $30,000. Resources Investment Advisors Inc. grew its holdings in shares of GW Pharmaceuticals PLC- by 51.9% in the 4th quarter. Resources Investment Advisors Inc. now owns 366 shares of the biopharmaceutical company’s stock worth $36,000 after purchasing an additional 125 shares during the last quarter. Horrell Capital Management Inc. grew its holdings in shares of GW Pharmaceuticals PLC- by 33.3% in the 4th quarter. Horrell Capital Management Inc. now owns 400 shares of the biopharmaceutical company’s stock worth $39,000 after purchasing an additional 100 shares during the last quarter. NumerixS Investment Technologies Inc bought a new stake in shares of GW Pharmaceuticals PLC- in the 4th quarter worth about $48,000. Finally, Advisory Services Network LLC grew its holdings in shares of GW Pharmaceuticals PLC- by 23.1% in the 4th quarter. Advisory Services Network LLC now owns 511 shares of the biopharmaceutical company’s stock worth $50,000 after purchasing an additional 96 shares during the last quarter. 72.67% of the stock is currently owned by institutional investors and hedge funds.
NASDAQ:GWPH traded up $2.96 during trading hours on Friday, hitting $174.97. 20,422 shares of the company traded hands, compared to its average volume of 546,605. The stock has a market cap of $5.19 billion, a P/E ratio of -16.53 and a beta of 2.79. GW Pharmaceuticals PLC- has a twelve month low of $90.14 and a twelve month high of $179.65. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.66 and a quick ratio of 6.34.
GW Pharmaceuticals PLC- (NASDAQ:GWPH) last announced its quarterly earnings results on Tuesday, November 27th. The biopharmaceutical company reported ($2.76) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($2.48) by ($0.28). The business had revenue of $2.40 million during the quarter, compared to the consensus estimate of $2.62 million. GW Pharmaceuticals PLC- had a negative net margin of 1,574.21% and a negative return on equity of 50.93%. The company’s quarterly revenue was down 4.0% compared to the same quarter last year. During the same period last year, the firm earned ($0.14) EPS. As a group, equities research analysts anticipate that GW Pharmaceuticals PLC- will post -10.18 EPS for the current year.
GW Pharmaceuticals PLC- Company Profile
GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms.
Featured Story: Yield Curve
No comments:
Post a Comment